NR
Vice President, Business Development
Get the full picture
Sign in to uncover key details.
Engeneic
Manufacturing · Australia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Bldg 53, L 4 11 Julius Ave, North Ryde, ...Website
www.engeneic.comRevenue
$5.2 MillionIndustry
About Engeneic
EnGeneIC specializes in the research, development, and manufacturing of targeted anti-cancer therapies, particularly through its innovative EDV nanocell platform. This first-in-class cyto-immunotherapy technology directly targets tumors while leveraging the patient's immune system. The company is currently conducting a Phase I/IIa clinical trial to assess the safety and efficacy of its EGFR-targeted EDV nanocells in patients with advanced solid tumors. EnGeneIC aims to bring its novel cancer therapies to market, with a focus on improving treatment outcomes for patients.Explore more
Engeneic Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Engeneic
Compare insights from companies similar to Engeneic, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Engeneic Tech Stack
A closer look at the technologies used by Engeneic
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Engeneic
Sign Up For FreeTo access detailed company insights
EnGeneIC specializes in the research, development, and manufacturing of targeted anti-cancer therapies, particularly through its innovative EDV nanocell platform. This first-in-class cyto-immunotherapy technology directly targets tumors while leveraging the patient's immune system. The company is currently conducting a Phase I/IIa clinical trial to... Read More
